#For patients

Written for adults considering a peptide as part of their health management.

Australian sales and PBS data show rapid GLP-1 medicine growth, with nearly half of estimated use accessed privately in the final study year.

A BMJ commentary frames AI as a commercial determinant of health. Persuasion and misinformation studies show why the concern deserves testing.

A UK model compared sleeve gastroplasty, sleeve gastrectomy and a gastric balloon with semaglutide over five years.

A Phase III trial found HD1916 met its prespecified equivalence criterion against reference semaglutide for weight change at 44 weeks.

A multicenter observational study linked injection pain during severe-asthma biologic treatment with higher treatment-aversion scores.

A 2026 paper describes reported oral and salivary symptoms with incretin medicines, but it does not establish causation for tirzepatide.

A six-trial meta-analysis linked GLP-1-based therapies to fewer apnea events, but high heterogeneity limits the pooled estimate.

What Ozempic and Wegovy labels say about diarrhea, why a symptom report cannot prove causation, and when official guidance calls for assessment.

A guide to Wegovy's official adverse-reaction and warning language, and why a forum report cannot diagnose what caused one person's symptoms.

A 2026 narrative review maps aesthetic-surgery concerns after GLP-1-related weight loss but reports no new trial or proven drug-specific effect.

SURPASS-EARLY found larger two-year HbA1c and weight reductions with tirzepatide than flexible conventional care in early type 2 diabetes.

A 2026 review links obesity treatment with better sleep-apnea measures. We separate its conclusions from the randomized tirzepatide evidence.